T2 Biosystems, Inc. (TTOO)

Market Cap	35.18M
Revenue (ttm)	27.55M
Net Income (ttm)	-60.64M
Shares Out	352.54M
EPS (ttm)	-0.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,875,865
Open	0.0954
Previous Close	0.0979
Day's Range	0.0954 - 0.1037
52-Week Range	0.0890 - 1.0800
Beta	0.48
Analysts	Buy
Price Target	0.20 (+100.4%)
Earnings Date	Nov 2, 2022

About TTOO

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream i...

• Industry: Biotechnology
• IPO Date: Aug 7, 2014
• CEO: John Sperzel
• Employees: 182
• Stock Exchange: NASDAQ
• Ticker Symbol: TTOO

Full Company Profile

Financial Performance

In 2021, T2 Biosystems's revenue was $28.06 million, an increase of 54.76% compared to the previous year's $18.13 million. Losses were -$49.24 million, 5.22% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TTOO stock is "Buy." The 12-month stock price forecast is 0.2, which is an increase of 100.40% from the latest price.

Price Target

$0.2

(100.40% upside)

Analyst Consensus: Buy

Stock Forecasts